Research Interests
I am interested in tumor immunology and developmental immunotherapeutics in gastrointestinal malignancies including gastric cancer, colorectal adenocarcinoma, pancreatic adenocarcinoma, cholangiocarcinoma, esophageal cancers, and hepatocellular carcinoma. My research focuses on metastatic mechanisms and how they influence tumor immune evasion during disease progression, particularly antigen presenting cells such as dendritic cells.
Selected Grants
Botensilimab and Balstilimab Optimization in Colorectal Cancer (BBOpCo)
Clinical TrialPrincipal Investigator · Awarded by Agenus, Inc. · 2024 - 2029A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of Vilastobart (XTX101) Monotherapy and Vilastobart (XTX101) and Atezolizumab Combination Therapy in Patients with Advanced Solid Tumors
Clinical TrialPrincipal Investigator · Awarded by Xilio Development Inc. · 2024 - 2029A Phase 1/1b Study of ASP2138 in Participants with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression
Clinical TrialPrincipal Investigator · Awarded by Astellas Pharma Global Development, Inc · 2024 - 2029A Phase 1/1b Study of ASP2074 in Participants with Metastatic or Locally Advanced Solid Tumors
Clinical TrialPrincipal Investigator · Awarded by Astellas Pharma Global Development, Inc · 2024 - 2028Botensilimab and Balstilimab Optimization in Colorectal cancer (BBOpCo)
Clinical TrialPrincipal Investigator · Awarded by Gateway for Cancer Research · 2024 - 2027Overcoming Anti-PD-1 Resistance in Melanoma by Targeting Immunologic Mediators of the Gli2 Pathway
ResearchCollaborator · Awarded by The Melanoma Research Foundation · 2022 - 2025The NLRP3-HSP70 Axis and Immunotherapy Resistance in Gastric Cancer
ResearchLaboratory Assistant · Awarded by American Association for Cancer Research · 2023 - 2024Expanded access use of MRTX849 for the treatment of patients with advanced solid tumors with a KRAS G12C mutation
Clinical TrialPrincipal Investigator · Awarded by Mirati Therapeutics, Inc. · 2022 - 2024Investigating the Role of EMT-mediated Dendritic Cell Tolerization in Checkpoint Inhibitor Resistance
ResearchPI-Fellow · Awarded by Damon Runyon Cancer Research Foundation · 2018 - 2022Investigating Oncogenic Signaling Pathways that Drive Wnt Ligand-mediated Immune Tolerance in Melanoma
ResearchPI-Fellow · Awarded by Conquer Cancer Foundation · 2017 - 2018External Relationships
- GLG Consultants
- IMS Consulting
- Society for immunotherapy of cancer
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.